Psychedelics Archives - Page 20 of 68

2 minute read

Terran Biosciences Steps Into 4-OH-DiPT Prodrug Arena With New Patent Application

July 18, 8:47 PM

As Reunion Neuroscience (NASDAQ: REUN) and Mindset Pharma (OTCMKTS: MSSTF) continue their court battle over claims on a novel 4-OH-DiPT prodrug, private biotech company Terran Biosciences has also filed a patent application over a proprietary polymorph,

MSSTF

2 minute read

PharmaTher’s DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage

By Lara Goldstein

July 18, 5:45 PM

PharmaTher Holdings (OTCQB: PHRRF) and the Terasaki Institute for Biomedical Innovation evaluated the former’s novel microneedle patch for the delivery of DMT, and research yielded positive outcomes.

PHRRF

2 minute read

Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At ‘Psychedelic-Assisted Therapies’

By Lara Goldstein

July 18, 3:54 PM

COMPASS Pathways (NASDAQ: CMPS) shared results from an open-label Phase 2 trial assessing its synthetic psilocybin COMP360 alongside SSRIs for Treatment-Resistant Depression (TRD.)

CMPS

2 minute read

Reunion Neuroscience On The Brink Of Going Private With Final Court Approval

By Lara Goldstein

July 17, 5:04 PM

Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution approving the proposed arrangement plan on July 12.

FTHWF

2 minute read

Enveric Unveils Positive Results From Animal Studies Of Its Psilocin Prodrug For Anxiety

By Vuk Zdinjak

July 17, 8:40 AM

Enveric Biosciences (NASDAQ: ENVB) announced positive results from pharmacokinetic animal studies demonstrating oral bioavailability, rapid onset of action and systemic clearance, and a more favorable side

ENVB

2 minute read

Venturing Beyond The Magic Kingdom: Former Disney CFO And Fortune 500 Veteran Takes The Reins At Lucy Scientific

By Lara Goldstein

July 14, 4:17 PM

As of July 13, Lucy Scientific Discovery (NASDAQ: LSDI) has a new principal.

AMGN

2 minute read

Psilocybin For IBS Gets FDA Nod To Begin Clinical Trials At Mass. General Hospital

By Lara Goldstein

July 13, 3:48 PM

Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at the Massachusetts General Hospital (MGH) on the effects of psilocybin-assisted psychotherapy for adults with Irritable B

TRYPF

2 minute read

Eight Capital Analyst Believes Canopy Should Not Be Valued As A Going Concern, Price Target $0

By The Dales Report

July 12, 10:09 AM

TerrAscend Corp. (OTC: TSNDF) has had a watershed moment, and Canopy Growth (NASDAQ: CGC) reaches $0 price target. Welcome to our latest Trade to Black podcast.

CGC

2 minute read

Bright Minds Goes For 5:1 Shares Consolidation, Hopes To Regain NASDAQ Compliance

By Lara Goldstein

July 11, 3:25 PM

Bright Minds Biosciences Inc. (NASDAQ: DRUG) is going for a consolidation of its common shares on a five-to-one basis, a plan approved by the company’s board of directors in June.

DRUG

3 minute read

Psyched: Australia’s Innovative Program, Congressional Amendments, Therapy Reimbursement And More

By Lara Goldstein

July 11, 11:25 AM

First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic stress disorder (PTSD) and psilocybin to combat treatment-resistant depression.

AWKNF